These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38462607)

  • 1. Predictive value of background parenchymal enhancement on breast magnetic resonance imaging for pathological tumor response to neoadjuvant chemotherapy in breast cancers: a systematic review.
    Li X; Yan F
    Cancer Imaging; 2024 Mar; 24(1):35. PubMed ID: 38462607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between background parenchymal enhancement and tumor response in patients with breast cancer receiving neoadjuvant chemotherapy.
    Rella R; Bufi E; Belli P; Petta F; Serra T; Masiello V; Scrofani AR; Barone R; Orlandi A; Valentini V; Manfredi R
    Diagn Interv Imaging; 2020 Oct; 101(10):649-655. PubMed ID: 32654985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting pathological complete response to neoadjuvant chemotherapy in breast cancer patients: use of MRI radiomics data from three regions with multiple machine learning algorithms.
    Zheng G; Peng J; Shu Z; Jin H; Han L; Yuan Z; Qin X; Hou J; He X; Gong X
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):147. PubMed ID: 38512406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response.
    Onishi N; Li W; Newitt DC; Harnish RJ; Strand F; Nguyen AA; Arasu VA; Gibbs J; Jones EF; Wilmes LJ; Kornak J; Joe BN; Price ER; Ojeda-Fournier H; Eghtedari M; Zamora KW; Woodard S; Umphrey HR; Nelson MT; Church AL; Bolan PJ; Kuritza T; Ward K; Morley K; Wolverton D; Fountain K; Lopez Paniagua D; Hardesty L; Brandt KR; McDonald ES; Rosen M; Kontos D; Abe H; Sheth D; Crane E; Dillis C; Sheth P; Hovanessian-Larsen L; Bang DH; Porter B; Oh KY; Jafarian N; Tudorica LA; Niell B; Drukteinis J; Newell MS; Giurescu ME; Berman E; Lehman CD; Partridge SC; Fitzpatrick KA; Borders MH; Yang WT; Dogan B; Goudreau SH; Chenevert T; Yau C; DeMichele A; Berry DA; Esserman LJ; Hylton NM
    Radiology; 2021 Nov; 301(2):295-308. PubMed ID: 34427465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased background parenchymal enhancement of the contralateral breast after two cycles of neoadjuvant chemotherapy is associated with tumor response in HER2-positive breast cancer.
    You C; Gu Y; Peng W; Li J; Shen X; Liu G; Peng W
    Acta Radiol; 2018 Jul; 59(7):806-812. PubMed ID: 29065702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between background parenchymal enhancement on breast MRI and pathological tumor response in breast cancer patients receiving neoadjuvant chemotherapy.
    Oh SJ; Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH
    Br J Radiol; 2018 Jul; 91(1088):20170550. PubMed ID: 29848015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between contralateral background parenchymal enhancement on MRI and outcome in patients with unilateral invasive breast cancer receiving neoadjuvant chemotherapy.
    Rella R; Bufi E; Belli P; Scrofani AR; Petta F; Borghetti A; Marazzi F; Valentini V; Manfredi R
    Diagn Interv Imaging; 2022 Oct; 103(10):486-494. PubMed ID: 35585020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in background parenchymal enhancement in HER2-positive breast cancer before and after neoadjuvant chemotherapy: Association with pathologic complete response.
    Dong JM; Wang HX; Zhong XF; Xu K; Bian J; Feng Y; Chen L; Zhang L; Wang X; Ma DJ; Wang B
    Medicine (Baltimore); 2018 Oct; 97(43):e12965. PubMed ID: 30412117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Background parenchymal enhancement in breast MRI before and after neoadjuvant chemotherapy: correlation with tumour response.
    Preibsch H; Wanner L; Bahrs SD; Wietek BM; Siegmann-Luz KC; Oberlecher E; Hahn M; Staebler A; Nikolaou K; Wiesinger B
    Eur Radiol; 2016 Jun; 26(6):1590-6. PubMed ID: 26382845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Background parenchymal enhancement and breast cancer: a review of the emerging evidences about its potential use as imaging biomarker.
    Rella R; Contegiacomo A; Bufi E; Mercogliano S; Belli P; Manfredi R
    Br J Radiol; 2021 Mar; 94(1119):20200630. PubMed ID: 33035073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinicopathological-imaging nomogram for the prediction of pathological complete response in breast cancer cases administered neoadjuvant therapy.
    Yang W; Yang Y; Zhang C; Yin Q; Zhang N
    Magn Reson Imaging; 2024 Sep; 111():120-130. PubMed ID: 38703971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast Cancer: Influence of Taxanes on Response Assessment with Dynamic Contrast-enhanced MR Imaging.
    Schrading S; Kuhl CK
    Radiology; 2015 Dec; 277(3):687-96. PubMed ID: 26176656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy.
    Nguyen AA; Arasu VA; Strand F; Li W; Onishi N; Gibbs J; Jones EF; Joe BN; Esserman LJ; Newitt DC; Hylton NM
    Tomography; 2020 Jun; 6(2):101-110. PubMed ID: 32548286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
    Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
    Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amount of fibroglandular tissue FGT and background parenchymal enhancement BPE in relation to breast cancer risk and false positives in a breast MRI screening program : A retrospective cohort study.
    Vreemann S; Dalmis MU; Bult P; Karssemeijer N; Broeders MJM; Gubern-Mérida A; Mann RM
    Eur Radiol; 2019 Sep; 29(9):4678-4690. PubMed ID: 30796568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative background parenchymal enhancement to predict recurrence after neoadjuvant chemotherapy for breast cancer.
    Moliere S; Oddou I; Noblet V; Veillon F; Mathelin C
    Sci Rep; 2019 Dec; 9(1):19185. PubMed ID: 31844135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Background parenchymal enhancement in the contralateral normal breast of patients undergoing neoadjuvant chemotherapy measured by DCE-MRI.
    Chen JH; Yu H; Lin M; Mehta RS; Su MY
    Magn Reson Imaging; 2013 Nov; 31(9):1465-71. PubMed ID: 23992630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of background parenchymal enhancement on breast MRI: a systematic review.
    Bignotti B; Signori A; Valdora F; Rossi F; Calabrese M; Durando M; Mariscotto G; Tagliafico A
    Br J Radiol; 2017 Feb; 90(1070):20160542. PubMed ID: 27925480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Machine learning with magnetic resonance imaging for prediction of response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis.
    Liang X; Yu X; Gao T
    Eur J Radiol; 2022 May; 150():110247. PubMed ID: 35290910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ring Enhancement in Non-Neoplastic Breast Tissue on MRI During Neoadjuvant Chemotherapy for Breast Cancer: Incidence and Clinical Implications.
    Oh J; Han BK; Ko EY; Ko ES; Choi JS; Kim H; Park YH; Kim JY
    Acad Radiol; 2023 Dec; 30(12):2931-2939. PubMed ID: 37045651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.